Largo Inc. (LGO)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	110.97	124.92	198.68	229.25	198.28	119.99
Revenue Growth (YoY)	-39.51%	-37.13%	-13.33%	15.62%	65.25%	14.16%
Cost of Revenue	112.61	127.34	170.69	167.42	133.01	88.39
Gross Profit	-1.65	-2.42	27.99	61.84	65.27	31.6
Selling, General & Admin	18.22	19.77	34.17	33.87	24.33	11.58
Other Operating Expenses	0.26	0.31	0.27	0.18	0.15	-1.47
Operating Expenses	24.51	27.12	45.9	44.62	33.54	14.77
Operating Income	-26.16	-29.54	-17.91	17.22	31.73	16.83
Interest Expense	-9.54	-9.15	-9.36	-1.46	-0.98	-1.14
Interest & Investment Income	1.34	1.52	2.02	1.11	0.4	1.15
Currency Exchange Gain (Loss)	-5.82	-12.52	-0.18	1.58	0.61	-9.06
Other Non Operating Income (Expenses)	-	-	-	0.06	-0.01	-0.05
EBT Excluding Unusual Items	-41.02	-49.68	-25.43	18.51	31.76	7.72
Asset Writedown	-27.09	-19.59	-8.93	-2.3	-	-
Other Unusual Items	-1.82	-1.97	-0.69	-12.17	-	-
Pretax Income	-64.75	-71.25	-35.06	4.04	31.76	7.72
Income Tax Expense	-17.99	-20.68	-2.7	6.27	9.19	0.96
Earnings From Continuing Operations	-46.76	-50.57	-32.36	-2.23	22.57	6.76
Minority Interest in Earnings	0.9	0.74	2.02	0.78	-	-
Net Income	-45.86	-49.83	-30.34	-1.45	22.57	6.76
Net Income to Common	-45.86	-49.83	-30.34	-1.45	22.57	6.76
Net Income Growth	-	-	-	-	233.84%	-
Shares Outstanding (Basic)	64	64	64	64	64	56
Shares Outstanding (Diluted)	64	64	64	64	65	61
Shares Change (YoY)	0.08%	0.08%	-0.63%	-0.92%	6.01%	14.69%
EPS (Basic)	-0.72	-0.78	-0.47	-0.02	0.35	0.12
EPS (Diluted)	-0.72	-0.78	-0.47	-0.02	0.35	0.11
EPS Growth	-	-	-	-	218.18%	-
Free Cash Flow	-49.99	-31.07	-42.46	-53.24	12.38	-77.61
Free Cash Flow Per Share	-0.78	-0.48	-0.66	-0.83	0.19	-1.26
Gross Margin	-1.48%	-1.94%	14.09%	26.97%	32.92%	26.33%
Operating Margin	-23.57%	-23.65%	-9.01%	7.51%	16.00%	14.02%
Profit Margin	-41.33%	-39.89%	-15.27%	-0.63%	11.38%	5.63%
Free Cash Flow Margin	-45.05%	-24.87%	-21.37%	-23.23%	6.24%	-64.69%
EBITDA	-0.07	-0.53	15.63	40.41	54.39	34.5
EBITDA Margin	-0.06%	-0.43%	7.87%	17.63%	27.43%	28.75%
D&A For EBITDA	26.09	29.01	33.54	23.19	22.66	17.67
EBIT	-26.16	-29.54	-17.91	17.22	31.73	16.83
EBIT Margin	-23.57%	-23.65%	-9.01%	7.51%	16.00%	14.02%
Effective Tax Rate	-	-	-	155.11%	28.93%	12.46%
Revenue as Reported	-	-	-	-	-	121.62

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q